|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia.
|
29437150 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Imatinib, a breakpoint cluster region-Abelson murine leukemia tyrosine kinase inhibitor, has revolutionized the treatment of chronic myelogenous leukemia (CML).
|
27875938 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used multiple, independent high-throughput drug sensitivity and resistance testing platforms that collectively evaluated 295 oncology compounds to characterize ex vivo drug response profiles of primary cells freshly collected from newly-diagnosed patients with BCR-ABL1-positive leukemia (n = 40) and healthy controls (n = 12).
|
28186983 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Established leukemia-specific predictive biomarkers for precision medicine include those genetic lesions such as BCR-ABL1 for Philadelphia-positive acute lymphoblastic leukemia and PML-RARα for acute promyelocytic leukemia.
|
28654205 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic myeloid leukemia (CML) is a stem cell-derived leukemia in which neoplastic cells exhibit the Philadelphia chromosome and the related oncoprotein BCR-ABL1.
|
28457753 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study further shows that the Wnt5a-haploinsufficient environment similarly affects BCR-ABL<sup>p185</sup> leukemia-initiating cells, which fail to generate leukemia in 42% of the studied recipients, or to transfer leukemia to secondary hosts.
|
27998927 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCR-ABL1-negative myeloproliferative neoplasms (MPNs) are clonal stem cell disorders defined by proliferation of one or more myeloid lineages, and carry an increased risk of vascular events and progression to myelofibrosis and leukemia.
|
28543980 |
2017 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report a third-generation sequencing assay on nanopore technology (MinION) for detecting BCR-ABL1 KD mutations and compare the results to a Sanger sequencing(SS)-based test in 24 Philadelphia-positive (Ph+) leukemia cases.
|
28663031 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, we found that microvesicles released from human leukemia cell line K562 (K562-MVs) containing BCR-ABL1 mRNA malignantly transformed normal hematopoietic transplants.
|
28836580 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fusion between breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog (ABL)-1 gene gives rise to BCR-ABL protein with a constitutive tyrosine kinase activity and transforms HSCs and/or hematopoietic progenitor cells (HPCs) into disease-propagating leukemia stem cells (LSCs) in chronic myeloid leukemia (CML).
|
28829353 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Approximately 10%-12% of patients in chronic-phase chronic myeloid leukemia (CP-CML) have additional chromosomal aberrations at diagnosis; moreover, CML occurs in up to 10% of pregnancy-associated leukemias, with an annual incidence of 1 per 100,000 pregnancies.
|
28721056 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The breakpoint cluster region (BCR) is known as a kinase and cause of leukemia upon fusing to Abl kinase.
|
27630163 |
2016 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, allosteric stimulation of ABL1 kinase activity enhanced the antileukemia effect of ABL1 tyrosine kinase inhibitors (imatinib and ponatinib) in human and murine leukemias expressing BCR-ABL1, TEL-ABL1, and NUP214-ABL1.
|
26864341 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This breakthrough revolutionized our knowledge related to leukemia biology and contemporary studies revealed that chromosomal translocation resulted in the fusion between the 5' segment of BCR gene and 3' segment of the ABL gene to form BCR/ABL fusion gene.
|
27894413 |
2016 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Specifically, it is associated to a particular cytogenetic abnormality, known as Philadelphia chromosome (Ph), which results from a fusion between part of the BCR ("breakpoint cluster region") gene from chromosome 22 and the Abelson (ABL) gene on chromosome 9 and leads to the formation a new gene leukemia-specific, the BCR-ABL.
|
27281463 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of BCR-ABL1 can explain virtually all the cellular features of the leukaemia (enhanced cell growth, inhibition of apoptosis, altered cell adhesion, growth factor independence, impaired genomic surveillance and differentiation).
|
25814077 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates for the first time the acquisition of additional BCR-ABL1 fusion genes through mitotic recombination in CML with cryptic BCR-ABL1.
|
26186983 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Leukemias expressing the constitutively activated tyrosine kinases (TK) BCR-ABL1 and FLT3/ITD activate signaling pathways that increase genomic instability through generation of reactive oxygen species (ROS), DNA double-strand breaks (DSB), and error-prone repair.
|
25828893 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
|
26243622 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural analysis to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukaemia.
|
25686603 |
2015 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, wild-type IKAROS restrains stemness properties and has tumor suppressor activity in BCR-ABL1-initiated leukemia.
|
24791856 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further gains in our understanding of the biology of Philadelphia chromosome-positive (Ph-positive) leukemia and mechanisms of resistance to BCR-ABL1 TKIs will benefit patients and also provide a blueprint for similar discovery in other cancers.
|
25700679 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the BCR-ABL1 kinase domain are an established mechanism of tyrosine kinase inhibitor (TKI) resistance in Philadelphia chromosome-positive leukemia, but fail to explain many cases of clinical TKI failure.
|
25134459 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.
|
26375673 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A kinase-independent role for Bcr-Abl in leukemia stem cells would imply that drugs that target Bcr-Abl's scaffolding ability or its DNA-binding ability should be used in conjunction with current therapeutic regimens to increase their efficacy and eradicate the stem cells of chronic myeloid leukemia.
|
24598782 |
2014 |